Gw Pharmaceuticals Share Discussion Threads

[future financier] 13/9/2016 14:27

Disappointing that the BBC could not find any space to mention GWP in this article

[123prezzie] 12/9/2016 17:04

FF makes a good point in post 8736 about being nervous over the price. How would FF feel if he/she were CEO? After nearly 20 years of graft, the only product revenue coming in is a measly amount from Sativex. Let's imagine that you banked several £ms late last year selling shares at 695p and shortly after were able to top up your options at a fraction of that price. If some competing potential purchasers appeared at a price above £10 (with a nice comfortable slot for FF as our our imaginary CEO)what then? There are lots of promising products in the pipeline, but they are still only promises.

[randompoint] 10/9/2016 20:55

FF sometimes seeking alpha is good. But can be v mixed bag

[ih_406638] 09/9/2016 18:22

FF, thanks for your post 8734. Interesting stuff

[masingi] 09/9/2016 17:13

Gadfly ^
This is why GWP is such a good punt. The market treats it like any other biotech with a wacky brand-new molecule to flog. It is vital to factor in that cannabis derivatives are not new by any measure.

[kdr246] 09/9/2016 16:27

Seeking alpha article was written by a new short as noted in last para.

[future financier] 09/9/2016 16:25

I guess I am just getting a bit paranoid with the prospect of either a jump in price due to a bid - or else a sell off if all comes to nowt!

[wengerb] 09/9/2016 16:14

FF. Take a look at Vitality Pharma's most recent accounts:



The company has very little cash and is running at a considerable loss. Maybe it can pay for its clinical trials with a credit card?

Might be tough raising any cash in its current state.

[future financier] 09/9/2016 15:42

How about this one as another potential thought piece (or whatever)

[future financier] 09/9/2016 15:32

I thought that seekingalpha was usually reasonably well informed - but I cannot refute your observations. Oh well better be more careful in future.

[wengerb] 09/9/2016 15:08

FutureFinancier.

I read the piece from your link and I didn't know whether to be shocked or amused.

I decided on both.

It's a preposterous fabrication by a self-declared shorter of GWPH.

Anyone reading it must ask himself or herself the question. Where's the denial from GWP and/or Morgan Stanley?

The underlying story asserts that GWP has been approached by several parties that have showed some interest in exploring M&A possibilities. As a result GWP has appointed Morgan Stanley as an advisor. If neither of these elements were true, GWP and MS would simply have had to issue a polite denial.

As RP points out, not to do so would be egregiously poor corporate governance.

If there are suitors, the timing is interesting as the phase III Lennox-Gastaut data due in September might well trigger bids. Successful LG-S data suddenly makes GWP a company with all the evidence it needs to submit an NDA, which in turn would lead pretty automatically to an approval. Prior to that data GWP remains something of a pig in a poke.

[randompoint] 09/9/2016 15:05

looks unlikely and illegal

[future financier] 09/9/2016 13:53

Underwriters offloading?

[kdr246] 09/9/2016 11:40

Looks like London is walking GW lower today which should give the buyers another chance

[randompoint] 08/9/2016 20:10

All the old puns:

[randompoint] 08/9/2016 19:29

...which seems to be their price target

[randompoint] 08/9/2016 19:26

kantar fitzgerald speculate $165

[altom] 08/9/2016 16:18

Wenger Thanks for putting me right. I had forgotten ADR's.

[nodding] 08/9/2016 15:22

I'm not ready for this!

The company must say something soonish. The "news" is obviously price sensitive. If they have not received a hard offer then they may be in discussion and that could delay the issue of a statement

[wengerb] 08/9/2016 13:33

Altom. A $250 price per ADR is equivalent to a UK ordinary share price of around £15.50. There are 12 UK shares in each ADR and then you have to correct for the exchange rate.